This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    747-207
Previous Study | Return to List | Next Study

Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) (AESOP)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Intercept Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT02177136
First received: June 26, 2014
Last updated: September 29, 2016
Last verified: September 2016
  Purpose
This is a phase 2, double-blind, placebo controlled trial in patients with primary sclerosing cholangitis to evaluate the effect of obeticholic acid on liver biochemistry, in particular, serum alkaline phosphatase; and, safety.

Condition Intervention Phase
Primary Sclerosing Cholangitis (PSC) Drug: OCA Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis

Resource links provided by NLM:


Further study details as provided by Intercept Pharmaceuticals:

Primary Outcome Measures:
  • Evaluate the effects of obeticholic acid (OCA) on serum alkaline phosphatase (ALP) in subjects with Primary Sclerosing Cholangitis (PSC) [ Time Frame: 24 weeks ]
  • Evaluate the effects of OCA on safety in subjects with PSC [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Hepatic biochemistry and indices of function [ Time Frame: 24 weeks ]
  • Hepatic Fibrosis [ Time Frame: 24 weeks ]
  • Gastrointestinal inflammation and disease [ Time Frame: 24 weeks ]
  • Farnesoid X receptor (FXR) activity [ Time Frame: 24 weeks ]
  • Inflammatory bowel disease (IBD) [ Time Frame: 24 weeks ]
  • Exposure response of total OCA (OCA and its conjugates) to biomarkers [ Time Frame: 24 weeks ]
  • Long-term efficacy [ Time Frame: 24 months ]
  • Long term safety [ Time Frame: 24 months ]
  • Disease-specific symptoms [ Time Frame: 24 weeks ]
  • Pharmacokinetics (PK) of OCA and other bile acids [ Time Frame: 24 Weeks ]

Enrollment: 77
Study Start Date: December 2014
Estimated Study Completion Date: June 2019
Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1.5 mg OCA titrating to 3 mg OCA
Subjects randomized to 1.5 mg will take 1.5 mg OCA daily for 12 weeks followed by 3 mg OCA for an additional 12 weeks.
Drug: OCA
Experimental: 5 mg OCA titrating to 10 mg OCA
Subjects randomized to 5 mg will take 5 mg OCA daily for 12 weeks followed by 10 mg OCA for an additional 12 weeks.
Drug: OCA
Experimental: Placebo
Subjects randomized to placebo will take placebo for 24 weeks
Drug: Placebo

Detailed Description:

This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding evaluation of the efficacy and safety of OCA in subjects with PSC. Approximately 75 subjects who provide written informed consent and meet all of the inclusion and none of the exclusion criteria will be randomized to 1 of 3 treatment groups as follows: 1.5 mg titrating to 3 mg OCA, 5 mg titrating to 10 mg OCA, or placebo, in a 1:1:1 ratio. Subjects will administer investigational product (IP) orally, once daily for 2 consecutive 12-week periods.

For the first 12 weeks, the subject's dose will be 1.5 mg OCA, 5 mg OCA, or placebo. After 12 weeks, the subject's dose will be titrated as follows, providing there are no limiting safety or tolerability concerns in the opinion of the investigator, while maintaining the trial blind: the 1.5 mg OCA treatment group will titrate to 3 mg, the 5 mg OCA treatment group will titrate to 10 mg OCA, and the placebo group will remain on placebo. Double-blind treatment will continue for a further 12 weeks at that dose.

Any subjects whose dose is not titrated, due to safety or tolerability concerns, will remain on their starting treatment (1.5 mg OCA, 5 mg OCA, or placebo) for the remainder of the double-blind phase to Week 24.

Randomization will be stratified by the presence or absence of concomitant ursodeoxycholic acid (UDCA) use and total bilirubin level (≤ 1.5x upper limit of normal [ULN] or > 1.5x ULN but < 2.5x ULN).

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female aged 18 to 75 years
  • Must provide written informed consent and agree to comply with the trial protocol
  • Must have a diagnosis of PSC (based on cholangiography at any point in time)
  • ALP at Screening ≥ 2x ULN
  • Total bilirubin at Screening < 2.5x ULN.
  • For subjects with concomitant IBD:

    1. Colonoscopy (if subject has a colon) or other appropriate endoscopic procedure within 12 months of Day 0 confirming no dysplasia or colorectal cancer
    2. Subjects with Crohn's Disease (CD) must be in remission as defined by a Crohn's Disease Activity Index (CDAI) <150.
    3. Subjects with ulcerative colitis (UC) must either be in remission or have mild disease. Remission is defined as a partial Mayo score of ≤2 with no individual sub-score exceeding 1. Mild disease is defined as a partial Mayo score ≤3 with no individual sub-score exceeding 1 point.
  • For subjects being administered UDCA as part of their standard of care, the dose must have been stable for ≥ 3 months prior to, and including, Day 0 and must not have exceeded 20 mg/kg/day during this time.
  • Subjects being administered biologic treatments (eg, anti-tumor necrosis factor (TNF) or anti-integrin monoclonal antibodies), immunosuppressants, systemic corticosteroids, or statins, must have been on a stable dose for ≥ 3 months prior to, and including, Day 0 and should plan to remain on a stable dose throughout the trial.
  • Contraception: female subjects of childbearing potential must use ≥ 1 effective method (≤1% failure rate) of contraception during the trial and until 4 weeks following the last dose of IP (including long term safety extension doses).

Exclusion Criteria:

  • Evidence of a secondary cause of sclerosing cholangitis at Screening
  • Immunoglobulin G4 (IgG4) > 4x ULN at Screening or evidence of IgG4 sclerosing cholangitis
  • Small duct cholangitis in the absence of large duct disease
  • Presence of clinical complications of chronic liver disease or clinically significant hepatic decompensation, including:
  • Current Child Pugh classification B or C
  • History of, or current diagnosis or suspicion of, cholangiocarcinoma or other hepatobiliary malignancy, or biliary tract dysplasia.
  • History of liver transplantation, or current model of end stage liver disease score ≥ 12
  • History of, or current, cirrhosis with complications, including history or presence of spontaneous bacterial peritonitis hepatocellular carcinoma or hepatic encephalopathy (as assessed by the investigator)
  • Current known portal hypertension with complications, including known gastric or large esophageal varices, poorly controlled or diuretic resistant ascites, history of variceal bleeds, or related therapeutic or prophylactic interventions (e.g., beta blockers, insertion of variceal bands or transjugular intrahepatic portosystemic shunt [TIPS])
  • History of, or current, hepatorenal syndrome (type I or II) or Screening serum creatinine > 2 mg/dL (178 μmol/L)
  • Platelet count < 50 x 10⁹/L
  • Current clinical evidence of dominant strictures that are considered clinically relevant in the opinion of the Investigator or current biliary stent at Screening
  • Current cholecystitis or evidence of current biliary obstruction due to gallstones. Asymptomatic gallstones that are not considered a safety risk in the opinion of the Investigator might be acceptable subject to discussion and agreement with the Medical Monitor.
  • Colonic dysplasia within ≤ 5 years prior to Day 0
  • History of small bowel resection
  • History of other chronic liver diseases, including, but not limited to, primary biliary cirrhosis (PBC), alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis, hepatitis B virus (unless seroconverted and no positive Hepatitis B Virus DNA), hepatitis C virus and overlap syndrome
  • Known Gilbert's syndrome or history of elevations in unconjugated (indirect) bilirubin >ULN or unconjugated (indirect) bilirubin >ULN at Screening
  • Known history of human immunodeficiency virus (HIV) infection
  • Currently experiencing, or experienced within ≤ 3 months of Screening, pruritus requiring systemic or enteral treatment
  • Known or suspected acute cholangitis in the 3 months prior to, and including, Day 0 including cholangitis treated with antibiotics
  • Administration of antibiotics is prohibited ≤1 month of Day 0 (unless subject is on a stable prophylaxis dose for at least 3 months prior to Day 0).
  • Administration of the following medications is prohibited ≤ 6 months of Day 0 and throughout the trial: fenofibrate or other fibrates and potentially hepatotoxic medications (including α-methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin).
  • IBD flare during Screening (up to and including Day 0), where "flare" is defined as follows:

    • UC flare: partial Mayo Score ≥5, and
    • CD flare: CDAI ≥250
  • Evidence of deleterious effects of alcohol abuse (as assessed by the investigator) or excessive alcohol consumption (>4 units/day for males, >2 units/day for females)
  • Known or suspected use of illicit drugs or drugs of abuse (allowed if medically prescribed or indicated) within 3 months of Day 0
  • If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating
  • Other concomitant disease, malignancy, or condition likely to significantly decrease life expectancy to less than the duration of the trial (e.g., moderate to severe congestive heart failure)
  • Participation in another investigational drug, biologic, or medical device trial within 30 days prior to Screening
  • History of noncompliance with medical regimens, or subjects who are considered to be potentially unreliable
  • Blood or plasma donation within 30 days prior to Day 0
  • Mental instability or incompetence such that the validity of informed consent or compliance with the trial is uncertain.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02177136

  Show 35 Study Locations
Sponsors and Collaborators
Intercept Pharmaceuticals
Investigators
Study Director: David Shapiro, MD Intercept Pharmaceuticals
  More Information

Responsible Party: Intercept Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02177136     History of Changes
Other Study ID Numbers: 747-207
Study First Received: June 26, 2014
Last Updated: September 29, 2016

Keywords provided by Intercept Pharmaceuticals:
PSC

Additional relevant MeSH terms:
Cholangitis
Cholangitis, Sclerosing
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on June 26, 2017